DFH Pharma

DFH Pharma is a clinical-stage biopharmaceutical company focused on developing oral enzyme therapies for metabolic and kidney-related diseases. The company's primary focus is on treating hyperoxaluria, a condition characterized by high levels of oxalate in the urine which leads to kidney stones and renal failure. Their lead candidate, DFH-001, is an oral oxalate decarboxylase enzyme designed to degrade oxalate within the gastrointestinal tract to prevent its absorption into the bloodstream. This approach aims to provide a safe and effective treatment for both Primary Hyperoxaluria and Enteric Hyperoxaluria. DFH Pharma is headquartered in Maryland and leverages expertise in enzyme engineering and gastrointestinal delivery.